Instrument Inactif

Autres langues Protalix Biotherapeutics Inc TEL AVIV STOCK EXCHANGE

Actions

US74365A1016

Produits pharmaceutiques

Autres langues

13/05	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)
13/05	Protalix: Q1 Earnings Snapshot
13/05	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
13/05	Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026
06/05	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
08/04	La historia de la semana: ¿Por qué el mercado bursátil israelí resiste tan bien?
19/03	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa
18/03	Top Midday Decliners
18/03	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/03	Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026
18/03	Protalix Biotherapeutics reports fiscal year 2025 financial and business results
18/03	Protalix: Q4 Earnings Snapshot
18/03	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
11/03	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
09/03	EU approves four-week dosing option for Chiesi and Protalix's Elfabrio
09/03	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
09/03	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio
04/03	Ellomay Capital Ltd. Announces Board and Committee Changes
11/02	Protalix BioTherapeutics : PLX Corporate Presentation (February 2026)
30/01	Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. Receive Positive CHMP Opinion for Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio (pegunigalsidase alfa) ? in EU
30/01	Protalix Fabry Disease Treatment Recommended for Approval by EMA Committee
30/01	Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU
05/01	Protalix BioTherapeutics Letter to Stockholders
17/12	Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications